NewAmsterdam Pharma Co N.V. Business Summary

NewAmsterdam Pharma Co N.V. (NAMS) is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin therapies for metabolic diseases, specifically targeting high-risk cardiovascular disease (CVD). The company’s business model is currently predicated on the clinical development and regulatory approval of its lead candidate, obicetrapib, a next-generation, once-daily, low-dose cholesteryl ester transfer protein (CETP) inhibitor. Revenue is primarily generated through strategic licensing agreements and milestone payments, most notably from its partnership with the Menarini Group for European commercialization, which contributed to a reported $22.5 million in revenue for fiscal year 2025. Operating as a single-segment entity, NewAmsterdam is transitioning toward a commercial-stage organization with Marketing Authorization Applications (MAAs) currently under review in Europe and the UK, and the initiation of new trials in Alzheimer’s disease planned for 2026. The company competes directly with established LDL-C lowering therapies such as Amgen’s Repatha, Novartis’s Leqvio, and Esperion’s Nexletol, positioning obicetrapib as a potent oral alternative to injectable PCSK9 inhibitors for patients who are statin-intolerant or require adjunct therapy. The leadership team is led by Chief Executive Officer Michael Davidson, M.D., a renowned lipidologist and former founder of Omthera Pharmaceuticals and Corvidia Therapeutics, and Chief Scientific Officer John Kastelein, M.D., Ph.D., a foundational figure in CETP research and the company’s founder. The executive suite includes Chief Financial Officer Ian Somaiya, a veteran of biotech investment banking, and Chief Business and Strategy Officer Juliette Audet, who transitioned from a partnership role at Forbion. The company was incubated by Forbion and maintains a high-pedigree board of directors that includes Mark C. McKenna (former CEO of Prometheus Biosciences), Wouter Joustra of Forbion, and Adele Gulfo. Supported by notable institutional investors such as Morningside Ventures and Frazier Healthcare Partners, NewAmsterdam maintains a robust capital position, reporting $728.9 million in cash and marketable securities as of year-end 2025 to fund its transition into a commercial-stage cardiovascular powerhouse.